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Abstract
Modifiers of Mendelian disorders can provide insights into disease mechanisms and guide
therapeutic strategies. A recent genome-wide association (GWA) study discovered genetic
modifiers of Huntington’s disease (HD) onset in Europeans. Here, we performed whole
genome sequencing and GWA analysis of a Venezuelan HD cluster whose families were
crucial for the original mapping of the HD gene defect. The Venezuelan HD subjects develop
motor symptoms earlier than their European counterparts, implying the potential for population-specific modifiers. The main Venezuelan HD family inherits HTT haplotype hap.03,
which differs subtly at the sequence level from European HD hap.03, suggesting a different
ancestral origin but not explaining the earlier age at onset in these Venezuelans. GWA analysis of the Venezuelan HD cluster suggests both population-specific and population-shared
genetic modifiers. Genome-wide significant signals at 7p21.2–21.1 and suggestive association signals at 4p14 and 17q21.2 are evident only in Venezuelan HD, but genome-wide significant association signals at the established European chromosome 15 modifier locus are
improved when Venezuelan HD data are included in the meta-analysis. Venezuelan-specific
association signals on chromosome 7 center on SOSTDC1, which encodes a bone morphogenetic protein antagonist. The corresponding SNPs are associated with reduced expression of SOSTDC1 in non-Venezuelan tissue samples, suggesting that interaction of
reduced SOSTDC1 expression with a population-specific genetic or environmental factor
may be responsible for modification of HD onset in Venezuela. Detection of population-specific modification in Venezuelan HD supports the value of distinct disease populations in
revealing novel aspects of a disease and population-relevant therapeutic strategies.
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Author summary
Huntington’s disease (HD) is a dominantly inherited neurodegenerative disorder caused
by a CAG trinucleotide expansion in HTT, which encodes huntingtin. HD involves various neurological manifestations such as involuntary movements, cognitive decline, and
personality change; age at onset of diagnostic signs is partly determined by the length of
the CAG repeat. However, genome-wide analysis of European HD subjects revealed that
age at onset corrected for individual CAG repeat size is modified by other genetic factors,
revealing potential disease-delaying pathways that form targets for therapeutic strategies.
In this study, we set out to identify genetic modifiers in a Venezuelan HD cluster whose
families were crucial for discovering the cause of HD. Through genome-wide association
analysis using age at onset corrected for CAG repeat size as the phenotype, we found
genome-wide significant (chromosome 7) and suggestive significant association signals
(chromosomes 4 and 17). Significant modification signals in Venezuelan HD appear to be
population-specific because genetic analysis of European HD subjects did not reveal modification signals at those locations. Nevertheless, established modification signals in European HD at a chromosome 15 locus were also augmented by Venezuelan HD data,
supporting the existence of both shared and population-specific genetic modifiers in HD.
Together with the full sequence of HTT shared by the majority of these Venezuelan HD
subjects, our genetic analysis provides insights into the geographical origin of the founder
mutation, meaningful allele-specific sites for gene targeting approaches, and potential targets for disease-modifying intervention in this population.

Introduction
Huntington’s disease (HD; MIM 143100), a familial neurodegenerative disorder characterized
by progressive movement disorder, cognitive decline, and psychiatric disturbances, is caused
by an expanded CAG glutamine codon repeat in HTT, which encodes huntingtin [1–3]. This
genetic defect was originally mapped to chromosome 4p16.3 using linkage analysis in part in
Venezuelan families from an HD population cluster whose generous participation in this fundamental HD genetic research also contributed, along with many North American and European families also carrying a CAG expansion mutation, to the discovery of HTT [3–6]. The
HTT repeat is polymorphic in the normal population [7], but inheritance of >35 CAGs can
lead to HD, while repeats of >40 CAGs are fully penetrant within a normal lifespan [8,9].
Expanded repeats show frequent germline instability so that HD individuals may not have a
CAG repeat length identical to their transmitting parent [10–12]. Rare de novo cases of HD are
generated sporadically in the population by intergenerational expansion of a normal length
CAG repeat [13,14]. The length of the inherited HTT CAG repeat is the primary determinant
of the age at onset of diagnostic neurological signs, accounting for ~65% of the variance in this
phenotype, with longer repeats leading on average to earlier clinical manifestations [7,15–18].
Individuals with biallelic HD mutations (i.e., HD homozygotes) have been reported and support complete dominance with respect to the pathogenic mechanism leading to disease manifestations since the age at onset of an individual with two expanded HTT CAG repeats is
comparable to that of a heterozygote with the longer of the two repeats [7,19]. Interestingly,
based upon one report, despite an age at onset similar to HD heterozygotes, individuals with
two expanded HTT CAG repeats may display more rapid decline in functional capacity [20].
Although the timing of disease onset is CAG repeat size-dependent, the duration of manifest
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disease (i.e., the length of time from onset to death) is not [21], suggesting that progression to
death involves different tissues or mechanisms than those leading to clinical onset. The relationship between CAG repeat size and HD clinical onset has played an important role in guiding 1) the generation of animal models [22–26], 2) design/interpretation of molecular studies
[27], and 3) identification of genetic modifiers [28].
The extensive accumulated experimental data and complete dominance of the mutant allele
are most consistent with a gain-of-function mechanism, which has prompted exploration of
mutant allele-specific interference with HTT expression as a treatment option [29]. Although
highly promising in model systems, gene-targeting approaches are just now beginning human
trials of safety and efficacy. An alternative strategy for the identification of therapeutic targets
is to capitalize on observations from humans with HD to discover naturally occurring modifiers of disease. Although CAG length accounts for a significant proportion of the variance in
HD age at onset [15,16,18], each CAG repeat size in the HD population is associated with a
wide range of onset ages [7]. Since individual differences between the observed age at clinical
onset and the age at clinical onset expected based upon the size of the mutation (i.e., residual
age at onset) are partially heritable [30,31], both genetic and environmental factors are thought
to influence the timing of onset in addition to CAG length [32]. The HD-associated CAG
expansion sits on diverse haplotypes [33–38], reflecting multiple independent mutation events
on different polymorphic chromosome backbones. However, none of the most frequent disease chromosome haplotypes is associated with a difference in age at onset [34], arguing that
HD is not commonly modified by a common cis genetic factor at HTT. Similarly, age at diagnostic motor onset of HD is not influenced by the length of the normal CAG repeat [7,32], or
by the presence of a second mutant allele [7], suggesting that heritable variance in age at onset
for a given CAG repeat is largely due to unlinked trans factors [39]. To identify these, we performed an initial genome-wide association (GWA) analysis in HD subjects of European
descent that revealed the first set of genome-wide significant loci associated with residual age
at onset of motor symptoms. Briefly, there were two independent onset modification signals
on chromosome 15 [28], one modification signal on chromosome 8 [28], and one modification signal on chromosome 3 [40]. Two of the modifier loci acted to delay onset and two acted
to hasten onset [28,40,41]. These findings established the proof-of-principle that the pathogenesis of HD can be altered prior to emergence of clinical disease. Consistent with single SNP
analysis results, pathway analysis supported a role for DNA repair/maintenance pathways in
modifying the age at onset of HD, suggesting that somatic size changes of the CAG repeat may
play a role in modification of the HD pathogenic process that leads to diagnostic clinical signs
[28]. Together, these observations demonstrated that genetic factors in humans are capable of
modifying the rate of HD pathogenesis prior to diagnosis and point to an approach based
upon such human observations for therapeutic targeting to delay HD onset.
Most genome-wide analyses to date have focused on Europeans, providing important but
potentially limited insights into the genetic contribution to disease risk and normal traits
(GWAS Catalog; https://www.ebi.ac.uk/gwas/). Our initial European HD GWA study [28] was
highly successful in revealing significant modifier loci of relatively strong effect based upon a
smaller sample size than most common disease genetic risk studies (GWAS Catalog; https://
www.ebi.ac.uk/gwas/). However, we might have missed genetic modifiers not present in Europeans. Here, we have extended our genetic analysis to the Venezuelan HD cluster of non-European HD subjects to: 1) determine the full sequence of HTT on the chromosome bearing the
CAG expansion mutation; 2) to investigate its origin, and 3) to determine whether modification of age at onset in this Venezuelan population is associated with specific naturally occurring genetic factors.
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Results
Venezuelan HD subjects
From 1979 to 1999, an interdisciplinary team of investigators annually visited Venezuela to
solicit the participation of a large cluster of HD families in research, to document their disease
and to obtain blood samples for DNA analysis and preparation of lymphoblastoid cell lines,
which were banked for future studies. These HD families contributed to both the localization
of the HD defect to chromosome 4 and to discovery of HTT and its expanded CAG repeat
mutation [3–6]. In 2004, a publication summarizing more than two decades of work by the U.
S.–Venezuela Collaborative Research Project described this HD cluster and presented evidence
for both genetic and environmental modifiers of HD [30]. For the current study, we prepared
DNA from lymphoblastoid cell lines banked prior to 1999 that had relevant clinical and/or
relationship information recorded. In all, we genotyped 443 HD and 106 related non-HD Venezuelan subjects using the Illumina Omni2.5 array platform [28] and performed genome-wide
imputation using the Michigan Imputation Server (https://imputationserver.sph.umich.edu/
index.html) with 1000 Genomes Project data (mixed population) as the reference panel. After
quality control (QC) analysis, 374 HD subjects carrying adult onset HD CAG repeat sizes
(CAG 40–55) with recorded age at onset of motor symptoms were analyzed in this study.
Ancestry of subjects was characterized by comparing to 1000 Genomes Project data (S1 Fig;
open black squares represent Venezuelan study subjects), which confirmed the strongest similarity with Columbians (pink square) and Puerto Ricans (pink cross). In addition, familial relationships were inferred based upon estimated IBD from the genome-wide genotype data (S2
Fig), revealing that subjects were from 22 families of quite variable size (S3 Fig). The largest
family, arbitrarily termed Family 1, comprised 218 HD individuals with the HD mutation on
hap.03, which matches the third most frequent disease chromosome in European HD subjects
(S3 Fig) [34,38]. Many of the smaller families (e.g., Family 6 and Family 12) also carry hap.03
and appear to be distantly related to members of the main family, consistent with pedigree
reconstruction by the U.S.-Venezuela Collaborative Research Project (S3 Fig). However, the
expanded HTT CAG repeats in some smaller families occur on different HTT haplotypes,
including hap.01 (the most frequent European HD haplotype), hap.02, hap.06, hap.07 and
hap.12 [34,38], indicating that most but not all HD chromosomes in the Venezuelan cluster
are ancestrally related.

Earlier age at onset in Venezuelan HD subjects
The mean CAG sizes across all haplotypes among the Venezuelans were 45.9 and 19 for longer
and shorter alleles, respectively, and the average age at onset was 35.5 (S4 Fig). The expected
decrease in onset age with increasing repeat length was readily observed in this data set (Fig
1A). Notably, 12 subjects carried two expanded alleles (Fig 1A; red circles), and, as predicted
from our previous European-based analysis [7], their ages at onset were best explained by the
longer allele in each individual (Fig 1A; shorter allele p-value in a regression analysis, 0.111),
supporting full dominance. Interestingly, as noted previously [32], the age at onset of Venezuelan HD subjects was distinctly earlier than that in European HD subjects (Fig 1B; ~5 years earlier). While such a difference could theoretically occur due to systematic biases in calling
motor onset in different countries/study populations, we believe this is unlikely because the
Venezuelan HD subjects show a disease duration (the time interval between onset and death,
which is CAG-independent) indistinguishable from European HD (Fig 1C; Wilcoxon test pvalue = 0.2783) [21]. The consistency of mean disease duration across populations [21,42]
argues that the earlier disease diagnosis for Venezuelan HD subjects does not represent a
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Fig 1. Earlier age at onset in HD subjects in Venezuela. (A) We evaluated the relationship between age at motor onset and the longer CAG repeat using the QC-passed
data set. Age at onset and the longer CAG repeat of HD homozygotes are indicated in open red symbols (12 individuals). (B) Age at onset of motor signs was plotted
against the size of expanded CAG repeat for HD subjects with European ancestry (blue) and Venezuelan HD subjects (red). Subsequently, log transformed age at onset
(natural log) was modeled as a function of CAG repeat length for each population in a linear regression model. Then, fitted values were transformed back into natural
scale age at onset for plotting. Blue and red lines represent regression models for European and Venezuelan HD, respectively. In addition, for a given CAG repeat size,
the average of age at onset of HD subjects carrying a hap.01 disease haplotype (circle) or a hap.03 disease haplotype (triangle) are marked. (C) Disease duration data were
compared between European and Venezuelan HD subjects. Duration values were available for 645 European HD and 85 Venezuelan HD subjects. Means of duration
were 15.4 and 15.7 for European and Venezuelan HD subjects, respectively (Wilcoxon test p-value = 0.2783).
https://doi.org/10.1371/journal.pgen.1007274.g001

systematic calling of the diagnosis earlier in the disease process, which would result in longer
durations, but rather truly reflects a more rapid CAG-dependent disease pathogenesis leading
to motor onset.
Among European HD subjects, residual age at onset (i.e., observed age at diagnostic motor
onset minus expected age at onset based on individual CAG repeat size) was not different
between HD subjects carrying different common haplotypes [34], and the HTT locus did not
emerge as associated with this phenotype in our GWA study of variations of >1% allele frequency [28]. For example, as summarized in Fig 1B, age at onset of European HD subjects
with hap.01 (the major European disease haplotype, blue circles) is very similar to that of European HD subjects with hap.03 (blue triangles). Similarly, although based on a small number of
samples, the most frequent Venezuelan haplotype hap.03 disease chromosomes (red triangles)
did not appear to be consistently associated with earlier age at onset compared to Venezuelan
hap.01 disease chromosomes (red circles). These data suggest that the striking difference in
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age at onset between European HD and Venezuelan HD subjects is not likely to be due to a
cis-factor on the hap.03 HTT haplotype.

Full sequence analysis of the Venezuelan hap.03 HTT haplotype
To more directly assess the possibility that the HD-associated Venezuelan hap.03 chromosome
carries novel genetic variations in HTT that are responsible for earlier onset than in Europeans,
we determined the HTT genomic sequence by whole genome sequencing of a representative
nuclear Venezuelan HD family from Family 1 (S1 and S5 Figs), carrying hap.03 as the mutant
haplotype. This nuclear family comprises 2 parents and 7 offspring (S5 Fig), so independently
phased sequences of each trio (S6 Fig) were merged to define the consensus allele of the
mutant HD chromosome at each site (Fig 2A). Except for some repeat regions and a small
number of inconsistent sites (S6 Fig), the sequence analysis determined 99.02% of HTT bases
of the Venezuelan hap.03 HD disease chromosome (Fig 2).
Compared with the hg19 reference sequence (chr4:3066408–3255687; hg19 coordinates),
the Venezuelan hap.03 disease chromosome carries alternative alleles at 28 variable sites,
including a novel SNP (rs966032869 in intron 56) that was not described previously in public
databases (Fig 2A). None of the variants at sites where Venezuelan hap.03 HD subjects carry
non-reference alleles: 1) changes an amino acid, 2) is located in a splicing site, or 3) is associated with altered HTT mRNA expression levels (based on GTEx portal; https://www.
gtexportal.org/home/). Additional Sanger sequencing analysis of HTT exon 1 revealed that
the affected parent of this family (S5 Fig) carries a typical codon configuration in the polyglutamine/polyproline region consisting of 45 pure CAGs, 1 CAA, 1 CAG, and downstream

Fig 2. Sequence of hap.03 mutant haplotype. (A) Based on consensus alleles in 7 phased haplotypes in the sequencing family, the hap.03 disease haplotype sequence
was reconstructed at the nucleotide level. Alleles on hap.03 that are different from the reference allele are shown with their genomic locations relative to HTT refseq
NM_002111. The previously reported sequence of hap.01 is also displayed. D, I and N represent deletion, insertion, and missing, respectively. (B) The region containing
the CAG repeat was missing in the sequencing data due to difficulty in aligning repeats. Thus, we performed additional Sanger sequencing to determine the sequence of
the HTT CAG repeat region and found that the transmitting HD parent has a typical repeat sequence and downstream elements: uninterrupted 45 CAG repeats, 1 CAA,
1 CAG, 1 CCG, 1 CCA, 7 CCG, and 2 CCT, comparable to the structure seen on the most frequent HD hap.01 chromosome in Europeans.
https://doi.org/10.1371/journal.pgen.1007274.g002
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elements of 1 CCG, 1 CCA, 7 CCGs, and 2 CCT codons (Fig 2B). These data collectively add
to the argument that variations at the HTT locus are not likely to underlie the earlier age at
onset in the Venezuelan HD subjects and suggest that this difference from European HD subjects may instead be due to unknown Venezuela-specific genetic and/or environmental factors
[32].

The origin of the CAG expansion mutation
Our full sequence data provide an unprecedented opportunity to assess the origin of the CAG
expansion mutation currently shared by most subjects in the Venezuela HD cluster. Consequently, we compared the full HTT sequence of the Venezuelan hap.03 HD chromosome to
European hap.03 disease chromosomes from HD subjects with Northern European, Spanish,
and Portuguese ancestries (S7 Fig). The European hap.03 HD chromosomes do not differ
from each other and are identical to the Venezuelan hap.03 HD chromosome at all but 2 sites:
the novel SNP (rs966032869) and one annotated rare SNP (rs192188940) (S7 and S8 Figs).
Interestingly, examination of these sites in a Brazilian HD subject carrying hap.03 revealed
identity with the European hap.03, supporting an independent origin of the Venezuelan
hap.03 HD chromosome.
Next, we compared the Venezuelan HD hap.03 sequence to 1000 Genomes Project data
(Phase 3) to identify normal control subjects who may have identical sequences. Among various populations in the 1000 Genomes Project data, including Africans, Ad Mixed Americans,
East Asians, Europeans, and South Asians, only one Mexican individual (NA19774) has
sequence identical across 5864 comparable variation sites to the Venezuelan hap.03 disease
chromosome, including at rs192188940 but excluding the novel SNP, rs966032869. The presence, but extreme rarity (MAF<0.001 based on UCSC Genome Browser) of rs192188940 on
both normal chromosomes in the general population and on the Venezuelan hap.03 HD chromosome is most consistent with the CAG expansion mutation having occurred on a normal
hap.03 chromosome that already carried the minor allele of this SNP. This normal chromosome may also have carried the rs966032869 minor allele or the latter may have arisen as a private mutation after CAG expansion. In any event, the most parsimonious explanation is that
the major HD chromosome in the Venezuelan HD cluster arose by an ancestral CAG expansion event distinct from that associated with the common European hap.03 haplotype, potentially in an individual already geographically located in South America.

Foundation for therapeutic strategies
We recently reported for the major European HD haplotype, hap.01, that an allele-specific
CRISPR/Cas strategy based upon pairs of PAM site-altering SNPs could be used to inactivate
the mutant HTT allele while leaving the normal HTT allele intact [43]. To provide the basis for
future exploration of this potential therapeutic approach to benefit the Venezuelan HD population, we capitalized on the full sequence data to reveal variation sites suitable for mutant
allele-specific silencing in this CRISPR/Cas strategy. Comparison to the haplotype most common in the normal population (i.e., hap.08 haplotype in 1000 Genomes Project, Phase 3 data)
revealed Venezuelan hap.03-specific NGG CRISPR/Cas9 PAM-sites. For example, two
CRISPR gRNAs depending on PAM-sites generated by rs2857935 and rs7659144 on the Venezuelan hap.03 would result in excision of the transcription start site and first two exons of the
mutant gene, completely preventing generation of mutant HTT mRNA (S9 Fig; red arrows).
This sequence-based precision medicine strategy holds promise for HD and other dominant
disorders [43], and the definition of CRISPR/Cas PAM sites specific to hap.03 ensures that if
substantial social, political, logistical and financial hurdles are overcome the development and
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consequent benefit of completely allele-specific gene targeting treatment strategies need not be
limited on scientific grounds to European populations but could be extended to the Venezuelan HD cluster.

Identification of genetic modifiers of disease onset in the Venezuelan HD
population
Population stratification makes a genome-wide approach to identify genetic factors that are
responsible for the earlier age at onset in combined Venezuelan and European HD subject
cohorts problematic. However, the broad distribution of age at onset within the Venezuelan
HD cohort does allow for statistical investigation of genetic modifiers present within this population using a GWA strategy. Consequently, we set out to identify genetic modifiers of HD in
the Venezuela cluster by modeling residual age at diagnostic onset as a function of a SNP genotype and other covariates in linear mixed effect models to correct for familial relationships.
Residual age at onset represents the difference between observed age at onset and expected age
at onset predicted from CAG repeat size in this population (Fig 1B, red line), thus reflecting
the degree of modification of onset age by factors other than CAG repeat size (S10 Fig). In a
GWA analysis of 374 Venezuelan HD individuals (Fig 3; S11 Fig), we observed one genomewide significant modifier locus on chromosome 7 (Fig 4) and loci of suggestive significance on
chromosomes 4 (S12A Fig) and 17 (S12B Fig). Considering the small sample size in our genetic
analysis, detection of genome-wide significant signals was surprising, although common modifiers may show stronger effect sizes than typical common disease risk alleles in GWA studies
[28]. In any event, additional analyses argue against statistical inflation (S11 Fig).

Population-specific modification signals
Interestingly, the chromosome 7 locus that shows genome-wide significant association signals
in the Venezuelan HD subjects (Fig 4A) was not significantly associated with residual age at
onset in European HD subjects (Fig 4B). The same is true for suggestive significant loci on

Fig 3. Genetic modifiers in Venezuelan HD subjects. Mixed effect linear regression analysis was performed for each SNP to determine the level of significance of the
SNP in explaining the variance in residual age at onset in Venezuelans. SNPs that have minor allele frequency greater than 5% are shown, revealing genome-wide
significant signals on chromosome 7. The X-axis and Y-axis represent chromosome and -log10(p-value), respectively. A dotted red horizontal line marks the level for
genome-wide significance.
https://doi.org/10.1371/journal.pgen.1007274.g003
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Fig 4. Genome-wide significant modification signals on chromosome 7 in Venezuelan HD. Association analysis results in Venezuelan HD (A) and in European HD
(B) are displayed for the chromosome 7 region. Each grey circle represents a SNP. Y-axis and X-axis represent significance (-log10(p-value)) and genomic coordinate
(hg19 assembly), respectively. Dotted red lines mark the level for genome-wide significance. Genes on the plus strand and negative strand are displayed in red and blue,
respectively. Recombination rate based on HapMap data is shown as a blue trace (secondary Y-axis). (C) For the top SNP in this region in Venezuelan HD analysis, allele
frequency, effect size, and p-values are shown for both Venezuelan HD and European HD. (D) In addition, a conditional analysis was performed focusing on the
chromosome 7 region in Venezuelan HD subjects to determine whether a cluster of significant SNPs in this region tags a single modification signal. SNPs in this region
were conditioned by the top SNP in the association analysis. Y-axis and X-axis represent significance in the conditional analysis and original association analysis.
https://doi.org/10.1371/journal.pgen.1007274.g004

chromosomes 4 and 17. The top SNP at the chromosome 7 locus, rs12668183, is associated
with a -2.8 year effect size per minor allele in Venezuelan HD, but no effect in European HD
subjects (Fig 4C; S13 Fig), indicating population-specific modification of HD. Intrigued by
this, we performed genetic modification score analysis using a polygenic risk score method to
compare these HD populations. Based upon association analysis results from European HD
subjects [28], we constructed a polygenic modification scoring routine using effect sizes of 44
independent suggestive SNPs (p-value < 0.00001) and the number of effect alleles of scoring
SNPs. Then the same scoring method was applied to the training set (European HD subjects)
and the Venezuela test set to judge how well the European-based HD modification score
explains phenotypic variance in the Venezuelan HD cluster. As anticipated, the European
polygenic modifier score explained a significant amount of variation in residual age at onset
among European HD subjects (S14A Fig; modifier score p-value < 2E-16; R-squared, 19.9%).
However, the modification score did not explain the variance in residual age at onset in the
Venezuelan HD subjects (S14B Fig; modifier score p-value, 0.75; R-squared, 0.03%). Consistent with the chromosome 7 modification signals, this difference may reflect a major contribution of population-specific factors to modification of HD.
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Fig 5. Improvement of chromosome 15 association signals by addition of Venezuelan HD data. (A) GWA analysis results for European HD subjects were combined
with those of Venezuelans in order to determine whether or not addition of Venezuelan data improved modification association signals. Association signals in
Europeans (X-axis) and that in Europeans + Venezuelans (Y-axis) are plotted. Open grey circles, which are above the red diagonal line, represent SNPs whose
significance in association analysis was improved when European and Venezuelan data were combined. (B) A regional association plot was generated focusing on
chromosome 15, revealing that rs150393409, which specifies an arginine to histidine missense alteration predicted to be deleterious to FAN1, is the most significant SNP
in this region. (C) A summary table is shown focusing on the top SNP in European + Venezuelan HD analysis.
https://doi.org/10.1371/journal.pgen.1007274.g005

The genetic modifier signals previously discovered on chromosomes 15, 8 and 3 in the
larger European HD GWA study [28] were not detected in the Venezuela HD GWA sample
(Fig 3). This is likely due to the reduced power of the much smaller Venezuela HD sample.
Indeed, the association signals at those loci that were genome-wide significant in European
HD subjects (both rare and common modifier signals) were modestly improved by adding
Venezuelan HD subject data into the meta-analysis (Fig 5A), consistent with these known HD
modifiers also acting to modify HD in Venezuelans. For example, on chromosome 15, when
meta-analysis was performed to combine European HD data and Venezuelan HD data, the
overall association signals were improved, revealing the strongest modification signal at the
SNP rs150393409, a predicted deleterious missense alteration in FAN1 that is likely to be the
functional variant responsible for modification (Fig 5B). Effect sizes for this SNP were similar
between the two populations (-6.4 and -5.5 years/minor allele, respectively) (Fig 5C). Together,
our association analysis results indicate that there may be both population-shared and population-specific modifying genetic factors that influence the rate of pathogenesis in HD.

PLOS Genetics | https://doi.org/10.1371/journal.pgen.1007274 May 11, 2018

10 / 25

Genetic modification of Huntington’s disease in Venezuela

Venezuelan-specific modification signals on chromosome 7
Focusing on the Venezuelan-specific modification signals on chromosome 7, the top SNP in
this region, rs12668183, is common in all 1000 Genome Project populations with minor allele
frequencies ranging from 30% in Europeans and 35% in the Ad Mixed Americans to 46% in
East Asians. When SNPs in this region were conditioned by rs12668183, no SNPs remained
significantly associated (Fig 4D), indicating that the significant SNPs all tag a single modifier
effect. The association signals were not contributed by CNV since the frequency of CNV in the
region was very low (S15A Fig) and when samples carrying CNV were excluded from the analysis, association signals were virtually unchanged (S15B Fig). The association signals were not
solely contributed by Family 1, since association analysis based separately on this family and
on all other families as a group generated similar significance levels (S16 Fig), suggesting
roughly equal contributions to the overall association signals. The association signals also were
not due to skewing of the quantitative analysis by a few inaccurately phenotyped individuals
since dichotomous analysis comparing allele frequencies of extreme residual age at onset
groups was consistent with the continuous QTL GWA analysis result (S17 Fig). The associated
SNPs tagged a single modifier haplotype at SOSTDC1 (Fig 4), which encodes a member of the
sclerostin family (https://www.ncbi.nlm.nih.gov/gene/25928) that functions as a bone morphogenetic protein (BMP) antagonist, and plays a role in signaling during cellular proliferation, differentiation, and programmed cell death [44–47]. Each minor allele of the top SNP
was associated with a hastening of onset by 2.8 years compared to those homozygous for the
major allele. The most significant SNPs associated with HD age at onset are located just 3’ to
SOSTDC1, and also show significant eQTL (expression quantitative trait loci) signals for
SOSTDC1 in the GTEx data set (http://www.gtexportal.org/home/eqtls/byGene?geneId=
sostdc1&tissueName=All) (Fig 6) whereas none of these SNPs show evidence of association
with expression of any of the other genes in the region. Interestingly, the minor alleles of SNPs
most significantly associated with modification of HD onset are associated with reduced

Fig 6. A potential role for reduced SOSTDC1 expression levels in HD onset modification. Modifier-associated SNPs in the chromosome 7 region were checked for
association with expression levels of SOSTDC1. The Y- and X-axes represent significances in GTEx eQTL and modification in our GWA analysis, respectively. Panel A
shows SNPs whose minor alleles are associated with decreased expression levels of SOSTDC1. Panel B shows SNPS whose minor alleles are associated with increased
expression levels of SOSTDC1.
https://doi.org/10.1371/journal.pgen.1007274.g006
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expression of SOSTDC1 in some GTEx tissues (e.g., ovary, artery-tibial, thyroid) (Fig 6A) but
not with increased expression (Fig 6B). This relationship supports the hypothesis that the
accelerated onset of HD caused by this modifier locus is due to reduced levels of SOSTDC1.

Discussion
Investigation of haplotypes in HD subjects, including family members from the large Venezuelan HD cluster and many families from North America and Europe, originally permitted
delineation of the chromosomal localization of the HD mutation [4–6,35], and ultimately led
to identification of the cause of the disease [3]. The most frequent HTT haplotype on HD chromosomes, currently named hap.01 [34,38,48] and defined by a standard panel of frequent
SNPs, accounts for the largest proportion of HD subjects of European ancestry [34,37,38], but
CAG expansions also occur on a variety of other haplotypes [33–38], indicating that multiple
mutational events have produced HD and emphasizing the unstable nature of HTT CAG
repeats [16,24,49,50]. The third most frequent HTT disease haplotype among HD subjects
throughout Europe is hap.03. Consistent with our observation of a Brazilian subject with a
hap.03 HD chromosome comparable to that in Northern European, Spanish and Portuguese
subjects, HTT CAG expansion mutations of HD subjects in Latin America have been hypothesized to be of European origin [51]. However, sequence differences on the Venezuelan HD
cluster hap.03 disease chromosome are most consistent with an independent origin of their
HD mutation, possibly due to CAG expansion in an individual in South America. With the
full sequence of the Venezuelan HD chromosome now available, a finer definition of the origin
of this disease mutation may ensue from the accumulation of more extensive genomic data
from geographically defined normal populations. Similar studies of other geographically separated HD clusters could also provide further insights into how normal range CAG repeats
expand into the disease-causing range, the emergence of new cases of HD and genetic
anticipation.
The discovery of the cause of HD made possible the generation of model systems [22] and
numerous hypotheses regarding disease mechanisms have subsequently been raised [1,9].
However, many mechanism-based therapeutic targets that were highly efficient in animal
models have turned out not to be effective in humans [52,53], perhaps due to species-specific
differences in the effects of, or in the response to, the HD mutation or to the use of extreme
CAG repeat lengths in most models. An alternative route to developing rational treatments is
to capitalize on the genetic information that can be obtained from studies of human HD subjects. We have pursued two distinct directions in this regard, both of which are augmented by
our findings concerning the Venezuelan HD cluster. The most readily definable therapeutic
target in HD is the mutant gene itself, since elimination of its expression would remove the
factor that ultimately precipitates all aspects of the disease. Our previous sequence analysis of
hap.01, the major European haplotype, enabled us to develop allele-specific CRISPR/Cas targeting strategies [38,43,48] to inactivate the mutant HTT allele without damaging the normal
HTT allele, providing a novel route to developing a treatment. The full sequence of the Venezuelan hap.03 HD chromosome and consequent definition of mutant allele-specific CRISPR/
Cas9 PAM sites supports this same approach, ensuring that further therapeutic development
of these allele-specific inactivation strategies need not be limited on scientific grounds to European HD subjects, but, if societal hurdles were overcome, could also benefit those in the Venezuelan HD cluster who have contributed so much to HD research. We have also reasoned that
more traditional pharmaceutical development for HD could benefit from rational, in-human
validated, therapeutic targets discovered by identifying genes that act to significantly modify
disease pathogenesis in the subjects themselves. The well-established inverse relationship
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between CAG repeat length and age at clinical onset of HD pointed both to the CAG repeat
size as the driver of the rate of HD pathogenesis and to a role for genetic and environmental
factors in modifying the impact of the CAG repeat [7,15–18,30–32,54]. Our haplotype analyses
indicated that other genetic variations at HTT are not a common source of HD modification
[34], yet the variance in age at onset at any given repeat length is large and heritable, so we pursued a GWA analysis of subjects of European ancestry to discover significant unlinked modifiers of the age at clinical onset. The most significant locus hastens onset by approximately 6
years per rare allele demonstrating that quite strong modifier effects are possible in humans
[28]. These modifier effects are due to naturally occurring variations in particular genes and
pathways, and it can be expected that pharmaceuticals developed to target the same pathways
could have even larger effects.
Our initial European HD GWA analysis and follow-up study highlighted the importance of
DNA maintenance/repair pathways in modifying the rate of CAG-dependent HD pathogenesis and suggested that somatic instability of the CAG repeat accelerates the disease [28,40].
While we saw some evidence that these processes also act to influence HD onset in Venezuela,
a much stronger result from our unbiased genetic study of Venezuelan HD subjects points to a
different modifier process. The genome-wide significant modification signals are focused at
SOSTDC1 (sclerostin domain containing 1) whose protein product functions as a bone morphogenetic protein (BMP) antagonist [46,55] and therefore negatively regulates BMP signaling. The expression of this gene is altered in various cancers [45,56–58]. The locus is also
associated with lipid-lowering in response to statins [59] (https://www.ebi.ac.uk/gwas/), providing a clear example of a phenotype determined by gene-environment interaction.
Compared to European HD, the Venezuelan HD subjects display a similar CAG size/age at
onset relationship, and full dominance of the longest CAG allele, but at equivalent CAG sizes,
they develop motor symptoms earlier, suggesting the potential for population-specific genetic
or environmental influences that accelerate HD pathogenesis. Our GWA analysis appears to
have detected one such locus, whose combination of high allele frequency (38%) and large
effect size (almost 3 years earlier onset per minor allele) made it detectable at genome-wide significance in only a few hundred Venezuela subjects. Population-specific modifiers of a disease
have been reported only rarely in the literature [60] but examples of population-specific disease risk association are reported frequently [61–67]. Population-specific studies can therefore
provide deeper insights into genetic architecture of human traits and diseases, although the relative contribution of population-specific variants, gene-gene interactions and gene-environment interactions has not been fully assessed. The fact that the chromosome 7 HD modifier
locus does not yield evidence of modification in European HD suggests that the modifier effect
is due either to a Venezuela-specific functional variant at the locus or to interaction of the
locus with some genetic or environmental feature specific to the Venezuelans. Assessment of
the former possibility will require detailed sequence comparison and functional dissection of
the locus, but the observation that the top SNPs are also associated with reduced expression of
SOSTDC1 in non-Venezuela data suggests that the second alternative is also worthy of consideration. Our data are consistent with the possibility that reduced expression of SOSTDC1 in
individuals carrying the chromosome 7 modifier haplotype interacts with a population-specific
factor to modify HD in Venezuela. A role for shared environmental factors in influencing age
at onset in the Venezuelan HD cluster has been proposed previously [32] and in an initial
assessment of potential genetic interaction involving the chromosome 7 locus, we detected
suggestive signals (S18 Fig) that might reflect functional genetic interaction. Identification of
the Venezuela-specific factor at the chromosome 7 locus, at an interacting locus, or in the environment that contributes to the modifier effect could yield insight into the mechanism of HD
and provide another route to treatment that might be applicable in both the Venezuelan and
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other HD populations. Interestingly, SNPs whose alternative alleles are associated with
increased levels of SOSTDC1 have much lower allele frequencies among our study subjects,
potentially explaining the failure to yield significant signals in the modifier GWA. However,
those alleles do show trends toward positive modification, implying that increased levels of
SOSTDC1 may delay age at onset in this population. From this perspective, identification of
factors that induce increased levels of SOSTDC1 may also have therapeutic utility.
In summary, our comprehensive genetic investigation of a distinct disease population has
revealed intriguing aspects of HD, which are directly relevant for gene-based and traditional
target-directed small molecule therapeutic development, both for this population and potentially for HD more generally.

Methods
Ethics statement
The study was approved by the Partners HealthCare Institutional Review Board as Protocol #:
2009P000566/PHS, “Genetic Variation that Modifies HD Phenotype” and performed on DNA
samples deposited previously, based upon oral consent, into a Partners HealthCare Institutional Review Board approved repository (currently Protocol# 2010P001611/PHS, “CHGR
Neurodegenerative Repository”).

Subjects, genotyping, quality control analysis, and genotype imputation
In a study approved by the Partners HealthCare Institutional Review Board, the Genetic Modifiers of HD (GeM-HD) Consortium carried out genotyping for 3,447 HD subject samples
from the Massachusetts Huntington’s Disease Center without Walls repository, which
included banked samples from North American, European and Venezuelan families who had
previously donated blood samples for HD research, and from the European Huntington’s Disease Network (EHDN) Registry study [68]. Data from Illumina Omni2.5 arrays were generated
at the Broad Institute and European HD subjects from this dataset (namely, HD GWA3) were
analyzed with previous HD GWA data in order to identify genetic modifiers of HD in Europeans [28]. 549 subjects from the Venezuela HD cluster, described in Wexler et al., 2004 [30],
were excluded from the previous analysis due to ancestry, and these form the primary population investigated in this study. As previously described [28], we applied quality control (QC)
metrics such as SNP call rate >95%, minor allele frequency (MAF) >1%, Hardy-Weinberg
equilibrium p-value >1E-6, sample call rate >95% to prepare high quality genotype data (538
subjects). Ancestry of samples was confirmed by principal components analysis using the
PLINK program [69]; MDS (multidimensional scaling) values of study subjects were compared to those of 1000 Genome Project samples. Familial relationships were determined based
on pair-wise IBD (identity-by-descent) estimation using the PLINK program and compared
with existing pedigree charts from the U.S.-Venezuela Collaborative Research Project [32]. For
a given individual, all related individuals with PLINK PI_HAT value greater than 0.125 were
identified, and grouped into a family. Subsequently, we checked if the rest of samples were
related to any of members of that family based on the same PI_HAT value criteria, and newly
discovered related individuals were merged with previously defined family. These procedures
were repeated exhaustively to identify all related subjects, generating 22 families with variable
sizes. Therefore, an individual within a given re-constructed family is related to at least one
other subject. Since we used estimated IBD values in identifying relatives to re-construct families, some families may have somewhat distantly related members. Haplotype phase of study
subjects was based on computational phasing of 21 tagging SNPs [34,38], generating the
names of haplotypes for each individual (e.g., hap.01 - hap.16). Since all HD subjects in each
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family share the same ancestral HD disease haplotype, the most frequent haplotype in the family was assigned as the HD disease chromosome haplotype. Genotype imputation was performed by the Michigan Imputation Server (https://imputationserver.sph.umich.edu/index.
html) using the 1000 Genomes Project mixed population as a reference panel. The SHAPEIT
phasing program (https://mathgen.stats.ox.ac.uk/genetics_software/shapeit/shapeit.html) was
used for pre-phasing study samples. The same QC parameters were applied to imputed data to
ensure the quality of genotype data.

CAG repeat size, age at onset of motor symptoms of HD, and residual age
at onset phenotype for genetic analysis
Methods to determine the sizes of HTT CAG repeats for each Venezuelan study subject are
described elsewhere [70]. Age at onset was determined either prospectively or retrospectively
based upon examination of subjects by experienced neurologists as described by the U.S.–Venezuela Collaborative Research Project [32]. Regression modeling analysis was performed to
describe the specific relationship between age at onset and CAG repeat size in these Venezuelans. Briefly, natural log transformed age at onset of Venezuelan HD and European HD were
modeled as a function of the size of expanded CAG repeat; study population-specific intercepts
were estimated by including a covariate specifying individual population in the regression
model. When a HD subject carries two expanded alleles (CAG > 35), the longer one was used
because of complete dominance [7]. This regression model described the overall relationship
between CAG and age at onset, and still permitted the revelation of any differences between
Venezuelan HD and European HD. Using this regression model, predicted age at onset was
estimated based on CAG repeat size, and subsequently was subtracted from actual age at onset
to calculate residual age at onset for each HD individual. Residual age at onset represents how
early or late a HD subject develops motor symptoms compared to expectation based on his or
her expanded CAG repeat length. A positive residual age at onset means an HD individual
developed symptoms later than expectation, and a negative residual age at onset means an HD
individual developed symptoms earlier than expectation.

Whole genome sequencing and phasing
For a selected nuclear family, where the HD mutation was transmitted on the hap.03 haplotype, we performed whole genome sequencing analysis as described previously [48]. Sequencing was performed by Complete Genomics, generating variant calling files containing
sequence variants with confidence scores. Since we aimed at maximizing SNP discovery and
the inclusion of related samples provided the opportunity to assess sequencing errors, we
examined all variants originally reported by Complete Genomics. For this study, we focused
on a genomic region (chr4:3066408–3255687; hg19 coordinates). Haplotype phasing was performed by using father-mother-child trio data as summarized in S5 Fig. Seven trios with a HD
parent, normal spouse and HD child were defined in this family, and therefore the same
parents were members of 7 trios, but data pre-processing and trio phasing was performed for
each trio independently. Briefly, a variant site was excluded in a given trio if 1) genotypes in all
3 individuals were unknown, 2) all 3 individuals were identically heterozygous or 3) a Mendelian error was detected. Since we aimed at maximizing variation coverage, we included sites
with partially missing data even though this makes detection of Mendelian errors difficult.
Thus, Mendelian error detection was based on checking the genotype data for the following: 1)
variant sites without any missing data, 2) sites with no missing data in the child and one or two
alleles missing in only one parent, and 3) sites with one allele missing in the child and none
missing in parents. This detection pipeline could still miss certain Mendelian errors due to
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missing genotypes, but these errors could be further identified by subsequent merging of multiple phased haplotypes in the family. After removing sites with Mendelian errors, sites that
could not be confidently phased due to missing genotypes, and sites heterozygous in all 3
members of the trio, we phased the alleles at all remaining sites to produce fully phased hap.03
disease haplotype for each trio.
After data pre-processing, trio genotype data were phased using the BEAGLE program
(https://faculty.washington.edu/browning/beagle/beagle.html), and the HD disease chromosome haplotypes were further analyzed. One hap.03 disease chromosome haplotype, inherited
from the father, was obtained for each of the seven trios, and we merged these to discover any
inconsistent alleles for additional QC analysis. Locations and numbers of Mendelian errors
and inconsistent alleles are summarized in S6 Fig. We then finalized the hap.03 disease haplotype by 1) taking alleles for sites with at least two phased allele calls, 2) assigning ‘N’ for sites
that were unphaseable, or had missing genotype or Mendelian errors, and 3) assigning ‘?’ for
the inconsistent sites. These procedures yielded phased haplotypes covering 99.02% of the sites
in the region. A novel SNP variation was identified, and submitted to dbSNP Build 150
(rs966032869).

Capture sequencing analysis of Venezuelan and European HD subjects
In order to validate Venezuelan HD whole genome sequencing data and compare to the
hap.03 disease chromosome in European HD subjects, we performed capture sequencing for
an additional 8 Venezuelan HD subjects and 7 unrelated European HD subjects. Haplotypes
of disease and normal chromosomes were based on computational phasing [34] of our GWA
samples [28]. Capture probes were designed to enrich the target region chr4:3066408–3255687
(hg19 coordinates) using the Agilent SureDesign online tool. This generated ultra-long
120-mer biotinylated complementary RNA baits, and these capture probes were used for solution-based SureSelect target enrichment. Briefly, genomic DNAs were sheared to produce
smaller fragments and libraries prepared with sequencer specific adaptors and indexes for
multiplexing. DNA libraries were hybridized with biotinylated cRNA baits, which were complementary to regions of interest. The bait-library complexes were pulled down by magnetic
beads. After the beads were washed, the RNA bait was digested to obtain the target DNA of
interest, and subjected to sequencing using Illumina HiSeq 100bp paired-end sequencing at
the Broad Institute. Sequence reads were aligned for variant calling using the Genome Analysis
Toolkit Best Practices workflow (https://software.broadinstitute.org/gatk/). Additional genotyping for specific sites was performed by conventional Sanger sequencing.

Genome-wide association analysis, conditional analysis, and extreme
dichotomous analysis
Residual age at onset was modeled by SNP, gender, and ancestry covariates (i.e., MDS 1–4) in
a linear mixed effect model based on kinship matrix using the GEMMA program (http://www.
xzlab.org/software.html). We applied an additive model for each SNP whose minor allele frequency is greater than 5% in the study population. GWA analysis using imputed genotypes
revealed genome-wide significant SNPs at a locus on chromosome 7. Subsequently, we compared genotypes (chr7: 16150000–16815000, hg 19) of 5 Venezuelan HD individuals who had
both sequence and imputed genotype data, revealing a mean concordance rate of 98.7%
(range, 98.2 ~ 99.3%).
Genomic inflation factor was calculated using the GenABEL package (median method)
(http://www.genabel.org/manuals/GenABEL). Recombination rate was obtained from HapMap data (http://www.sanger.ac.uk/resources/downloads/human/hapmap3.html), and plotted
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on the secondary Y-axis of regional association plots. In order to determine dependency of
SNPs in a given region, linear mixed effect models were constructed similarly but included the
most significant SNP as a covariate. Significances of SNPs in the ordinary association analysis
were compared to those in conditional analysis. Also, we performed extreme dichotomous
analysis to determine whether a small number of data points drove the significant association.
We directly compared SNP allele frequencies of those individuals whose residual age at motor
onset was among the 10% extremes of earlier and later than expected onset. Logistic regression
analysis was performed using the GEMMA program.

CNV analysis, meta-analysis, and polygenic modification score analysis
Genome-wide copy number variation was determined from GWA data using PENNCNV program (http://penncnv.openbioinformatics.org/en/latest/). For chromosome 15 region, we
meta-analyzed association analysis results of Venezuelan HD and European HD using the
METAL program (https://genome.sph.umich.edu/wiki/METAL_Documentation). In order to
determine whether a polygenic modification score based on European HD subjects captured
individual deviation from the expected age at onset for a given CAG size in Venezuelan HD,
we obtained effect sizes and significances of SNPs based on the European HD subjects. Polygenic modification score is defined as the sum of effect allele count X effect size for each HD
subject. We used independent SNPs with suggestive significance (p-value < 0.00001). This
scoring method was applied to European HD and Venezuelan HD to calculate individual
modification score. Subsequently, polygenic modification score was used as the independent
variable with gender and ancestry covariates to explain residual age at onset in each
population.

GTEx eQTL analysis
For SNPs in the chromosome 7 region, we evaluated the significance of eQTL with genes in
the region using the GTEx portal data base (http://www.gtexportal.org/home/). Among ISPD,
SOSTDC1, and LRRC72, ISPD and SOSTDC1 generated significant eQTL signals in GTEx data
set, and therefore these SNPs were downloaded for subsequent analysis. 42 and 231 SNPs
(non-unique) were significantly associated with expression of ISPD and SOSTDC1 in various
human tissues, respectively. For those significant eQTL SNPs, we compared the significance
(-log10(p-value)) in our modifier association analysis to those in GTEx cis eQTL analysis,
revealing a correspondence between GWA significance and eQTL significance only for
SOSTDC1.

Potential genetic interaction with chromosome 7 modifier locus
Venezuelan HD subjects were separated into two groups based on chromosome 7 modifier
genotype (rs12668183), resulting in rs12668183-carriers and non-rs12668183-carriers. For
each group of Venezuelan HD subjects, independent GWA analysis was performed. In order
to reduce outlier effects in the continuous analysis, subjects were sorted based on residual age
at onset, and top and bottom 40% of subjects were analyzed using dichotomized phenotype
data, focusing on comparing allele frequency differences between early and late onset groups.
Mixed effect models were used to correct familial relationship.

Supporting information
S1 Fig. Ancestry characteristics of Venezuelan HD subjects. In order to confirm ancestry of
Venezuelan HD study subjects, principal components analysis using genome-wide SNP data
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of samples was performed together with 1000 Genomes Project data (Phase 3; 2,504 samples
from 26 populations). The first vs. second MDS (multidimensional scaling) values (top row),
and the third vs. fourth MDS values (bottom row) were plotted. 1000 Genomes Project samples are represented by colored symbols (A and B), or open grey symbols (C, D, E, and F).
Study subjects used for GWA analysis (C and D) or sequencing analysis (E and F) are indicated
by open black squares. For detailed description of populations and symbols of 1000 Genomes
Project, refer to http://www.internationalgenome.org/faq/which-populations-are-part-yourstudy/.
(PDF)
S2 Fig. Familial relationships of study subjects. For QC-passed 374 Venezuelan HD study
subjects analyzed in GWA analysis, familial relationships were inferred based on genome-wide
genotype data. Pair-wise IBD (identity-by-descent) values were estimated by the PLINK program. From 374 unique study subjects, IBD values were estimated for 69,751 meaningful pairs.
The mean of PI_HAT value (indicative of IBD) was 0.0253 (A). Based on Z1 and Z2 values
from the PLINK IBD estimation, we identified 170 unique parent-child pairs comprising 216
subjects (B, red rectangle). In addition, siblings and other relationships were also revealed (B).
(PDF)
S3 Fig. Reconstruction of families based on genome-wide genotype data. Based on pairwise IBD estimations, families were reconstructed. A pair of related individuals whose PLINK
PI_HAT value was greater than 0.125 (representing first cousin or closer relationships) were
combined, and this process was repeated exhaustively until all related individuals were combined, generating 22 families with variable sizes. Therefore, an individual within a given reconstructed family has at least one relative. Families were numbered arbitrarily and were separated by blue boundary line. The size of each family is provided in a parenthesis, and haplotype
of HD disease chromosome is indicated in parenthesis after slash. Unrelated individuals (18)
are at the bottom-right of the plot without family name.
(PDF)
S4 Fig. Descriptive statistics of Venezuelan HD study subjects. Following sample QC analysis, 374 Venezuelan HD subjects including 12 homozygote HD individuals were analyzed. Histogram plots show distributions of longer CAG repeats (A), shorter CAG repeats (B), and age
at onset of motor symptoms (C). The means of longer CAG, shorter CAG, and age at onset of
motor symptoms are 45.9 (A), 19 (B), and 35.5 (C), respectively.
(PDF)
S5 Fig. HD nuclear family used for whole genome sequencing analysis. Nine subjects
including one non-HD parent were used for whole genome sequencing. This family inherits
the hap.03 haplotype on the mutant chromosome as the majority of Venezuelan HD subjects
do. For each subject, haplotypes of mutant chromosome (red) and normal chromosome
(black) are indicated. In addition, to determine the phased sequence of HTT in this family, we
performed trio phasing for each trio comprising parents and a child. As indicated by "Trio #",
7 trios were used for phasing analysis. For each trio phasing a small number of Mendelian
errors were detected. Diamond symbols were used for children to maintain confidentiality.
(PDF)
S6 Fig. Summary of sequencing and phasing analysis of HTT locus. (A) For each trio, trivial
phasing analysis was performed using the BEAGLE program, and 7 phased mutant chromosomes were merged to identify consensus alleles of hap.03 disease haplotype in this family. We
detected 6 unique Mendelian error sites, 3,231 unphaseable sites due to missing data, and 7
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inconsistent sites. In total 99.02% of bases were determined. Examples of inconsistent sites are
shown in panel B. N and D represent missing and deletion.
(PDF)
S7 Fig. Venezuelan mutant hap.03-specific sequence variations.
(A) Northern (filled blue circles) or Southern European HD subjects (filled purple and orange
circles representing Spanish and Portuguese HD, respectively) carrying hap.03 as the mutant
chromosome were identified using phased haplotypes of GWA data. A scatter plot shows
MDS 1 and 2 values from principal components analysis of GWA data relative to control populations such as CEU and TSI.
(B) Consensus alleles of the hap.03 haplotype in Venezuelan HD were obtained from trio phasing of family samples. In addition, consensus alleles of the hap.03 disease haplotype in 7 independent Northern European HD subjects were obtained from capture sequencing analysis (7
samples). Direct comparisons of consensus alleles revealed 2 sites (including a novel SNP)
where alleles are different between Venezuelan and European hap.03 disease haplotypes. For
the known SNP site (rs192188940), imputed GWA data for Spanish (15 samples) and Portuguese HD (43 samples) with hap.03 haplotype are also indicated. Since the novel SNP is not
part of the 1000 Genomes Project reference panel, rs966032869 was not imputed in GWA
data.
(PDF)
S8 Fig. Validation of Venezuelan HD-specific variation sites. Sanger sequencing analysis
was performed to validate the genotypes of Venezuelan hap.03-specific SNPs including a novel
SNP. A panel of hap.03 HD subjects from Northern Europe (1 sample), Spain (4–6 samples),
Portugal (4–6 samples), and Brazil (1 sample) were sequences, and representative sequencing
analysis results are shown.
(PDF)
S9 Fig. Allele-specific CRISPR/Cas9 target sites for Venezuelan HD subjects carrying
mutant hap.03 haplotype. Fully reconstructed Venezuelan hap.03 sequences were compared
to consensus allele of hap.08 allele from 1000 Genomes Project data (phase 3). Haplotype
hap.08 represents the most common normal chromosome in Europeans and Americans (1000
Genomes Project, phase 3). A consensus sequence of hap.08 from the 1000 Genomes Project
data represents the most frequent allele for a given site. Subsequently, we determined those
PAM-altering SNPs that create and eliminate CRISPR/Cas9 PAM sites (NGG) in hap.03 and
hap.08 haplotypes, respectively. In the region, 16 variations create NGG PAM sites only in
hap.03 and therefore can be used for allele-specific CRISPR/Cas9 targeting aiming at silencing
the mutant allele. Red arrows show an example where simultaneous application of CRISPR
gRNAs is expected to selectively eliminate the transcription start site and expanded CAG
repeat in the mutant HTT.
(PDF)
S10 Fig. Distribution of residual age at onset in Venezuelan HD subjects. In order to generate phenotype data for GWA analysis aiming at discovering modifiers of HD subjects in Venezuela, a regression model described in Fig 1B was used to calculate the difference between
observed age at onset and predicted age at onset based on CAG repeat size. Distributions of
residual age at onset in Venezuelans were visually compared that in European HD subjects
previously described. The mean and median of residual age at onset in Venezuelan HD were
0.368 and 0.403, respectively.
(PDF)
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S11 Fig. Quantile-quantile (QQ) plot. Levels of genomic inflation were assessed based on QQ
plot. The inflation factor was 1.0197 by the median method.
(PDF)
S12 Fig. Suggestive association signals on chromosomes 4 and 17. Suggestive modification
signals on chromosome 4 (A) and 17 (B) are displayed. X-axis and Y-axis represent genomic
coordinate (hg19) and -log10(p-value), respectively. Each grey circle is a SNP, and cyan trace
represents recombination rates (secondary Y-axis) based on HapMap data. All exons were
combined to represent a gene, in red or blue to represent genes on plus and minus strand,
respectively.
(PDF)
S13 Fig. Population-specific modification by rs12668183 on chromosome 7. Residual age at
onset of HD subjects carrying 0, 1, or 2 minor alleles of the top SNP (i.e., rs12668183) are plotted for Venezuelan HD (A) and European HD subjects (B). Red horizontal lines represent
mean residual age at onset.
(PDF)
S14 Fig. Genetic modification score based on European HD subjects. Independent suggestive significant or higher SNPs in European HD subjects were used as a training set to construct the polygenic modification score of each HD subject. Briefly, for a given individual,
effect sizes of SNPs were multiplied by the number of effect alleles to calculate the sum of the
modification score. The same scoring method was applied to European HD subjects to estimate the maximum prediction power of the modification score (A). Next, the effect sizes and
scoring SNPs based on European HD subjects were applied to calculate the genetic modification score of Venezuelan HD subjects and subsequently used to explain residual age at onset of
Venezuelan HD subjects (B). For each HD population, residual age at onset was modeled as a
function of genetic modification score to judge its significance.
(PDF)
S15 Fig. Lack of contribution from CNV.
(A) Focusing on the chromosome 7 region that generated genome-wide significant modification signals in Venezuelan HD, frequencies of CNVs are plotted over SNP association analysis
results (grey circles). Black, blue, and red lines represent all CNVs, duplication, and deletion,
respectively. Primary and secondary Y-axes represent SNP significances and frequencies of
CNVs, respectively. X-axis represent genomic coordinate based on hg19 assembly.
(B) In order to judge the levels of contribution of CNV to significant modification signals in
the chromosome 7 region, samples carrying CNVs were excluded for SNP association analysis
in a mixed effect model. X-axis and Y-axis represent association analysis results using all samples (374 subjects) and those using samples w/o CNVs (317 subjects). Significance means
-log10(p-value).
(PDF)
S16 Fig. Equal contribution from the main family and other families. In order to determine
whether the genome-wide significant modification signals were largely contributed by the
main family, we split the data into the main family (218 subjects) and other families (156 subjects). Subsequently, statistical analysis was performed to determine whether residual age at
onset in the main family was significantly different from that in the other families (A).
(B) Chromosome 7 top SNP (i.e., rs12668183) was also analyzed independently in the two
groups to assess the significance in modification.
(PDF)
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S17 Fig. Extreme dichotomous analysis. As a confirmatory analysis of continuous phenotype
data analysis, we performed extreme dichotomous analysis. Instead of using continuous residual age at onset data, we generated two groups representing the 10% extremes of age at onset.
We then compared allele frequency of the markers between the extreme early onset group and
the extreme late onset group. The X-axis represents continuous association analysis results
using all samples, and Y-axis represents extreme dichotomous association analysis.
(PDF)
S18 Fig. Potential genetic interaction with chromosome 7 modifier. We attempted to detect
genetic interactions with chromosome 7 modifier locus. Venezuelan HD subjects were
grouped by a chromosome 7 modifier SNP rs150393409; minor allele-carriers (A; 238 subjects)
and non-carriers (B; 136 subjects). For each group, samples with top and bottom 40% residual
age at onset were identified. Subsequently, GWA analysis was performed using dichotomized
phenotype data in mixed effect model (see method section). Although not genome-wide significant, some regions in the genome suggested modification of HD in the presence (e.g., chromosome 8 in panel A) or absence (chromosome 12 in panel B) of chromosome 7 onset
modifier.
(PDF)
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